Remedy

Abstract

It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis. As a result, the macrophages with dysfunction are normalized, macrophages infected with a pathogen are exterminated or a pathogen in the infected macrophages is exterminated.

1 . A remedy wherein phagocytic activity of macrophages is facilitated and all or a part of the pathogens present in the macrophages are exterminated to vanish.  
   
   
       2 . A remedy wherein phagocytic activity of macrophages is facilitated and pathogen-retaining macrophages are led to cell death.  
   
   
       3 . A remedy wherein phagocytic activity of macrophages is facilitated and it acted upon the macrophages in a dysfunctional state.  
   
   
       4 . The remedy according to  claim 1 , for mycobacteriosis, AIDS, chlamydiosis or toxoplasmosis.  
   
   
       5 . The remedy according to  claim 2 , for Crohn's disease, rheumatoid, cancer or immunodeficiency syndrome.  
   
   
       6 . The remedy according to  claim 1 , wherein said macrophages are resident in mucosal tissue.  
   
   
       7 . The remedy according to  claim 1 , wherein said macrophages are resident in any of peritoneal cavity, greater omentum, milky spot, pulmonary alveolus, pulmonary stroma, liver, portal vein area, spleen, bone marrow, thymus, digestive tract, palatine tonsil, adrenal gland, pituitary, thyroid stroma, Langerhans islet, parathyroid gland, pineal gland, testis, ovary, oviduct, uterus, placenta, skin, meningis, brain substance and choroid plexus, or the above macrophages are microglia, precursor cells of microglia, glia cells, precursor cells of glia cells, precursor cells of the above resident macrophages, analogous cells of the above resident macrophages, or precursor cells of the above resident macrophage analogous cells.  
   
   
       8 . The remedy according to  claim 1 , comprising PLGA [poly(lactic acid/glycolic acid)copolymer] and being for tuberculosis.  
   
   
       9 . The remedy according to  claim 8 , further comprising rifampicin.  
   
   
       10 . The remedy according to  claim 1 , comprising PLGA where a molecular weight is 1,500 to 150,000.  
   
   
       11 . The remedy according to  claim 1 , comprising PLGA where a molecular weight is 1,500 to 75,000.  
   
   
       12 . The remedy according to  claim 1 , further comprising at least one of PVA (polyvinyl alcohol), PEG (polyethyleneglycol), PEO (polyethylene oxide), sugar, protein, peptide, phospholipid or cholesterol.  
   
   
       13 . The remedy according to  claim 8 , comprising at least one of PVA, PEG, PEO, sugar, protein, peptide, phospholipid or cholesterol, and being a fine particle formulation wherein major particle diameters are 1 to 6 μm.  
   
   
       14 . The remedy according to  claim 1 , wherein the phagocytic activity of the macrophages is facilitated by being phagocytosed.  
   
   
       15 . The remedy according to  claim 1 , comprising PLGA where a molecular weight is 5,000 to 20,000 and being for tuberculosis.  
   
   
       16 . The remedy according to  claim 15 , fabricated by membrane emulsification method.  
   
   
       17 . The remedy according to  claim 2 , comprising lipopolysaccharide of Pantoea agglomerans and being for AIDS.  
   
   
       18 . The remedy according to  claim 3 , comprising lipopolysaccharide of Pantoea agglomerans and having cytotoxic effect on lung cancer cells.